Table 2.
Clinicopathological features associated with LNM in EGC patients.
| Clinicopathological features | LNM | χ2 | P | ||
|---|---|---|---|---|---|
|
Present (n = 49) (%) |
Absent (n = 273) (%) |
||||
| Gender | Male | 30 (13.7) | 189 (86.3) | 1.220 | 0.318 |
| Female | 19 (18.4) | 84 (81.5) | |||
| Tumor location in the stomach | Upper third | 7 (10.0) | 63 (90.0) | 1.988 | 0.370 |
| Middle third | 12 (15.6) | 65 (84.4) | |||
| Lower third | 30 (17.1) | 145 (82.9) | |||
| Age (year) | <65 | 26 (12.4) | 183 (87.6) | 3.549 | 0.073 |
| ≥65 | 23 (20.3) | 90 (79.6) | |||
| Tumor size (cm) | <2 | 15 (8.9) | 154 (91.1) | 11.923 | 0.003 |
| 2–2.9 | 18 (20.0) | 72 (80.0) | |||
| ≥3 | 16 (25.4) | 47 (74.6) | |||
| Macroscopic type | Elevated | 5 (19.2) | 21 (80.8) | 2.102 | 0.350 |
| Flat | 4 (8.5) | 43 (91.5) | |||
| Depressed | 40 (16.1) | 209 (83.9) | |||
| Depth of invasion | Intramucosal | 9 (5.8) | 147 (94.2) | 25.132 | 0.000 |
| SM1 | 6 (14.3) | 36 (85.7) | |||
| SM2 | 34 (27.4) | 90 (72.6) | |||
| Lauren classification | Intestinal | 14 (7.5) | 172 (92.5) | 29.467 | 0.000 |
| Diffuse | 7 (14.3) | 42 (85.7) | |||
| Mixed | 25 (34.2) | 48 (65.8) | |||
| Not defined | 3 (21.4) | 11 (78.6) | |||
| Histological classification | Well | 2 (4.7) | 41 (95.3) | 15.146 | 0.001 |
| Moderately | 17 (10.7) | 142 (89.3) | |||
| Poorly | 30 (25.0) | 90 (75.0) | |||
| Lymphovascular invasion | Absence | 18 (6.7) | 251 (93.3) | 91.795 | 0.000 |
| Presence | 31 (58.5) | 22 (41.5) | |||
| Perineural invasion | Absence | 43 (14.0) | 265 (86.0) | 8.640 | 0.011 |
| Presence | 6 (42.9) | 8 (57.1) | |||
| Helicobacter pylori infection | Absence | 33 (14.7) | 192 (85.3) | 0.134 | 0.737 |
| Presence | 16 (16.5) | 81 (83.5) | |||
| TANs | Low | 17 (8.9) | 175 (91.1) | 14.669 | 0.000 |
| High | 32 (24.6) | 98 (75.4) | |||
| CAFs | High | 39 (27.9) | 101 (72.1) | 36.499 | 0.000 |
| Low | 6 (3.5) | 164 (96.4) | |||
| Neutrophil count | average ± SD | 3.23 ± 1.43 | 3.42 ± 1.36 | F = 0.129 | 0.393 |
| NLR | Low ( ≤ 1.9) | 25 (15.5) | 136 (84.5) | 0.000 | 1.000 |
| High (>1.9) | 24 (14.9) | 137 (85.1) | |||
LNM, lymph node metastasis; TANs, tumor-associated neutrophils; CAFs, cancer-associated fibroblasts; NLR, neutrophil-to-lymphocyte ratio.